Joint Research Agreement
Xeureka Inc. and UBE Corporation have entered into a joint research agreement focused on small-molecule drug discovery in the oncology field. This collaboration aims to create novel drug candidate compounds for cancer therapy.
Technological Approach
Xeureka will utilize its advanced computational drug discovery technologies, including its proprietary Free Energy Perturbation (FEP) program, to identify new small-molecule compounds. These compounds will target promising molecules specified by UBE.
Pre-Collaboration Validation
Before formalizing the agreement, both companies confirmed the applicability and accuracy of Xeureka's FEP technology for the research targets, leading to the decision to proceed with the collaboration.
Financial Terms
Under the agreement, Xeureka will receive an upfront payment from UBE and is eligible for milestone payments based on future research progress.
